The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Press & News

2017-09-06

Solna, Sweden, September 6, 2017. Affibody AB (“Affibody”), a clinical stage next generation biopharmaceutical...[read more]

Affibodys latest Press releases

To the archive

2017-09-06

Affibody Announces Presentation of Interim Data from Phase I/II Clinical Trial of ABY-035 at European Academy of Dermatology and Venereology

Solna, Sweden, September 6, 2017. Affibody AB (“Affibody”), a clinical stage next generation biopharmaceutical company developing a portfolio of innovative drug projects, today announced...[read more]

2017-08-23

Interim Report – January to June 2017...[read more]

2017-05-24

Kallelse till årsstämma...[read more]

Affibody´s strengths and advantages

About Affibody

Our mission

Our mission is to improve the lives of patients with serious diseases by being a research-driven company with a long term commitment to development of proteinbased drugs.

Technology

Affibody is developing innovative protein therapeutics in areas where our unique technology platforms gives us the advantage.

Highly qualified resources

Operations are conducted by highly qualified resources in research and development and is based on the company's proprietary technology platforms.